An observational study in Open Angle Glaucoma, sponsored by iSTAR Medical. Active, not recruiting at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by iSTAR Medical · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Glaucoma, Open-Angle by iSTAR Medical — 1 open to participants now, 5 under way, none of them phase 3. Glaucoma, Open-Angle · iSTAR Medical.
Among the 10 studies in Glaucoma, Open-Angle by iSTAR Medical, this one is the only one that started in 2022, is one of 3 observational ones, and was the 9th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →1 of the 10 studies in Glaucoma, Open-Angle by iSTAR Medical is open now, in 3 countries. Recruiting first, the newest first:
iSTAR Medical · Sites in Panama, Spain, United Kingdom
Ages 40+
By country, each count listing its studies:
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2022.
This study's planned enrollment of 320 is above the median of 101 across 184 observational studies indexed under Glaucoma, Open-Angle.
Median enrollment 30 across the 7 interventional studies, 116 across the 3 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
iSTAR Medical is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
2 of the studies in Glaucoma, Open-Angle by iSTAR Medical that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04524416iSTAR MedicalMINIject Global Long-Term Follow-up Study | 2026-12 |
| NCT05024695iSTAR MedicalEvaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma. | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Glaucoma, Open-Angle by iSTAR Medical, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
As part of the post-market clinical follow-up (PMCF), this registry is developed to ensure real-world data collection on MINIject device.
The goal of the registry is to collect data of the MINIject in a real-life setting. The registry has 3 main objectives: the collection of real-world evidence on the usability of the device, the patient reported outcomes, and the device safety over a period of 2 years after surgery.
patient diagnosed with open angle glaucoma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
each participant receives an implant Miniject and are followed during 2 years
Unexpected incidents and/or serious reportable incidents
Collection of incidents (nature (ocular or non-ocular), number and severity) throughout the study. The number of unexpected incidents and the number of individuals presenting at least one event will be reported.
Time frame: From enrollment up to 2 years after surgery (study completion)
Surgeon assessment of Device Usability
The Device usability will be assessed by the surgeon using a study-specific usability questionnaire evaluating device preparation, handling, and use during surgery. Questionnaire items may include categorical ratings, ordinal scales, and free-text comments, as applicable.
Time frame: The surgery day
Eye-related Quality of Life Assessed Using the SHPC-18 questionnaire
Quality of life will be assessed using the Symptom and Health Problem Checklist (SHPC-18) questionnaire, an 18 item instrument for patients treated for glaucoma. The questionnaire includes two domains: local eye symptoms (7 items) and Visual function problems (11 items). Each item is scored and a total "bothersome score" is calculated by summing all 18 items (range 0-1800) and dividing by 18, resulting in a final score ranging from 0 to 100. Higher scores indicate greater symptom burden and worse quality of life. Change from baseline will be evaluated at 12 and 24 months.
Time frame: Baseline, 12 and 24 months
IOP measurement
IOP measurements at each follow-up visit over time and changes compared to baseline
Time frame: Baseline, 1 day and 1, 3, 6, 12 and 24 months
Ocular medication use
Ocular medication use at each follow-up visit and changes compared to baseline
Time frame: From enrollment through 2 years after surgery
Investigator Assessment of Ocular Symptoms Using a 6-Category Severity Scale
At each follow-up visit, the investigator will assess the presence and severity of ocular symptoms (including blurred vision, glare, halos, dryness, foreign body sensation, and other reported symptoms) using the categories: absent, mild, moderate, severe, very severe, or unknown. Changes from baseline will be evaluated.
Time frame: From enrollment until 2 years post-surgery
BCVA testing
Best Corrected Visual Acuity (BCVA) outcomes at each follow-up visit and changes compared to baseline
Time frame: Baseline, 1, 3, 6, 12, 24 months
Visual field
Visual field outcomes at each follow-up visit and changes compared to baseline
Time frame: Baseline, 6, 12 and 24 months
Additional ocular surgery post-implantation
Additional ocular surgery post-implantation will be registered through the study
Time frame: From surgery until 2 years post-surgery
Started Jul 2022 (actual). Primary completion is estimated for Dec 2028, 77 months after the start.
Of 53 observational studies under Glaucoma, Open-Angle, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12. This study's planned 77 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
iSTAR Medical